Hutchison China MediTech Ltd – (NASDAQ:HCM) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus target price of $18.67 for the company and are anticipating that the company will post $0.13 earnings per share for the current quarter, according to Zacks. Zacks has also given Hutchison China MediTech Ltd – an industry rank of 109 out of 265 based on the ratings given to related companies.

HCM has been the subject of several recent analyst reports. Zacks Investment Research raised Hutchison China MediTech Ltd – from a “sell” rating to a “hold” rating in a research note on Tuesday, September 13th. Beaufort Securities reaffirmed a “buy” rating on shares of Hutchison China MediTech Ltd – in a research note on Tuesday, June 21st. Canaccord Genuity reaffirmed a “buy” rating on shares of Hutchison China MediTech Ltd – in a research note on Tuesday, August 2nd. Finally, Stifel Nicolaus set a $20.00 target price on Hutchison China MediTech Ltd – and gave the stock a “buy” rating in a research note on Monday, August 1st.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/hutchison-china-meditech-ltd-nasdaqhcm-given-18-67-average-target-price-by-analysts.html

Hutchison China MediTech Ltd – (NASDAQ:HCM) traded down 0.41% on Tuesday, hitting $12.24. The company had a trading volume of 41,350 shares. The stock has a 50 day moving average of $12.71 and a 200-day moving average of $13.11. Hutchison China MediTech Ltd – has a one year low of $9.80 and a one year high of $14.70. The stock’s market capitalization is $1.48 billion.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Folger Hill Asset Management LP purchased a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at about $1,130,000. Indus Capital Partners LLC raised its position in shares of Hutchison China MediTech Ltd – by 6.3% in the second quarter. Indus Capital Partners LLC now owns 1,383,893 shares of the company’s stock valued at $18,198,000 after buying an additional 81,550 shares during the last quarter. Allianz Asset Management AG raised its position in shares of Hutchison China MediTech Ltd – by 5.7% in the second quarter. Allianz Asset Management AG now owns 351,400 shares of the company’s stock valued at $4,621,000 after buying an additional 19,000 shares during the last quarter. GRATRY & Co LLC purchased a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at about $157,000. Finally, Baillie Gifford & Co. purchased a new position in shares of Hutchison China MediTech Ltd – during the second quarter valued at about $1,970,000.

Hutchison China MediTech Ltd – Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

5 Day Chart for NASDAQ:HCM

Get a free copy of the Zacks research report on Hutchison China MediTech Ltd – (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hutchison China MediTech Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.